Lexicon Pharmaceuticals LXRX is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here’s what investors need to know before the announcement.
Analysts estimate that Lexicon Pharmaceuticals will report an earnings per share (EPS) of $-0.16.
Lexicon Pharmaceuticals bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Past Earnings Performance
Last quarter the company missed EPS by $0.00, which was followed by a 2.7% drop in the share price the next day.
Here’s a look at Lexicon Pharmaceuticals’s past performance and the resulting price change:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.16 | -0.18 | -0.18 | -0.16 |
| EPS Actual | -0.16 | -0.17 | -0.16 | -0.13 |
| Price Change % | -2.7% | 1.93% | -13.86% | -1.12% |
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.16 | -0.18 | -0.18 | -0.16 |
| EPS Actual | -0.16 | -0.17 | -0.16 | -0.13 |
| Price Change % | -2.7% | 1.93% | -13.86% | -1.12% |
Stock Performance
Shares of Lexicon Pharmaceuticals were trading at $2.38 as of July 29. Over the last 52-week period, shares are down 34.76%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Image and article originally from www.benzinga.com. Read the original article here.